CY1114993T1 - Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου - Google Patents

Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου

Info

Publication number
CY1114993T1
CY1114993T1 CY20141100112T CY141100112T CY1114993T1 CY 1114993 T1 CY1114993 T1 CY 1114993T1 CY 20141100112 T CY20141100112 T CY 20141100112T CY 141100112 T CY141100112 T CY 141100112T CY 1114993 T1 CY1114993 T1 CY 1114993T1
Authority
CY
Cyprus
Prior art keywords
breast cancer
methods
gene expression
subject
subtype
Prior art date
Application number
CY20141100112T
Other languages
English (en)
Inventor
Charles M Perou
Joel S Parker
James Stephen Marron
Andrew Nobel
Philip S Bernard
Matthew Ellis
Elaine Mardis
Torsten O Nielsen
Maggie Cheang
Original Assignee
The University Of North Carolina At Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of North Carolina At Chapel Hill filed Critical The University Of North Carolina At Chapel Hill
Publication of CY1114993T1 publication Critical patent/CY1114993T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Παρέχονται μέθοδοι για ταξινόμηση και για αξιολόγηση της πρόγνωσης ενός υποκειμένου που έχει καρκίνο μαστού. Οι μέθοδοι περιλαμβάνουν πρόβλεψη υπότυπου καρκίνου μαστού χρησιμοποιώντας εποπτευόμενο αλγόριθμο εξασκημένο για να στρωματοποιεί υποκείμενα επί τη βάσει εγγενούς υπότυπου καρκίνου μαστού. Το μοντέλο πρόβλεψης βασίζεται επί του προφίλ έκφρασης γονιδίου των εγγενών γονιδίων που απαριθμούνται στον πίνακα 1. Αυτό το μοντέλο πρόβλεψης μπορεί να χρησιμοποιηθεί για να προβλέπεται επακριβώς ο εγγενής υπότυπος ενός υποκειμένου που διαγνώσκεται με καρκίνο μαστού ή είναι ύποπτο να έχει καρκίνο μαστού. Περαιτέρω, παρέχονται συνθέσεις και μέθοδοι για πρόβλεψη έκβασης ή απόκρισης σε θεραπεία ενός υποκειμένου που έχει διαγνωστεί με καρκίνο μαστού ή είναι ύποπτο ότι έχει καρκίνο μαστού. Αυτές οι μέθοδοι είναι χρήσιμες για καθοδήγηση ή προσδιορισμό εκδοχών θεραπείας για ένα υποκείμενο προσβεβλημένο με καρκίνο μαστού. Μέθοδοι της εφεύρεσης περαιτέρω περιλαμβάνουν μέσα για αξιολόγηση προφίλ έκφρασης γονιδίου που συμπεριλαμβάνει μικροδέσμες και ποσοτικές δοκιμασίες αλυσιδωτής αντίδρασης πολυμεράσης, καθώς επίσης κιτ που περιλαμβάνουν αντιδραστήρια για εφαρμογή των μεθόδων της εφεύρεσης.
CY20141100112T 2008-05-30 2014-02-17 Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου CY1114993T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5750808P 2008-05-30 2008-05-30
EP09770678.2A EP2297359B1 (en) 2008-05-30 2009-06-01 Gene expression profiles to predict breast cancer outcomes

Publications (1)

Publication Number Publication Date
CY1114993T1 true CY1114993T1 (el) 2016-12-14

Family

ID=41202871

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100112T CY1114993T1 (el) 2008-05-30 2014-02-17 Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου

Country Status (13)

Country Link
US (7) US9631239B2 (el)
EP (2) EP2664679B1 (el)
JP (3) JP5740302B2 (el)
AU (1) AU2009262894B2 (el)
CA (1) CA2725760C (el)
CY (1) CY1114993T1 (el)
DK (1) DK2297359T3 (el)
ES (2) ES2650610T3 (el)
HR (1) HRP20140140T1 (el)
PL (1) PL2297359T3 (el)
PT (1) PT2297359E (el)
SI (1) SI2297359T1 (el)
WO (1) WO2009158143A1 (el)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5740302B2 (ja) * 2008-05-30 2015-06-24 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール
US9512484B2 (en) * 2009-01-23 2016-12-06 Bergen Teknologioverforing As Methods for determining a prognosis for survival for a patient with breast cancer
US9771618B2 (en) 2009-08-19 2017-09-26 Bioarray Genetics, Inc. Methods for treating breast cancer
WO2011061568A1 (en) * 2009-11-22 2011-05-26 Azure Vault Ltd. Automatic chemical assay classification
KR101864855B1 (ko) 2010-03-31 2018-07-13 지피돈 디아그노스틱스 게엠베하 내분비 치료 중 유방암 재발 예측 방법
WO2012106718A2 (en) * 2011-02-04 2012-08-09 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
AU2012229123B2 (en) * 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
US20140228241A1 (en) 2011-07-28 2014-08-14 Sividon Diagnostics Gmbh Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrentbreast cancer
MX359664B (es) 2011-07-29 2018-10-05 Univ Colorado Regents Tratamiento de cáncer de mama.
CN104024851A (zh) * 2011-11-28 2014-09-03 加拿大国家研究委员会 针对癌症的紫杉醇反应标志物
AU2012345789B2 (en) * 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
AU2013266419B2 (en) * 2012-05-22 2018-09-27 British Columbia Cancer Agency Branch NANO46 genes and methods to predict breast cancer outcome
US9939533B2 (en) 2012-05-30 2018-04-10 Lucerno Dynamics, Llc System and method for the detection of gamma radiation from a radioactive analyte
US9002438B2 (en) 2012-05-30 2015-04-07 Lucerno Dynamics System for the detection of gamma radiation from a radioactive analyte
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
WO2014005010A2 (en) 2012-06-29 2014-01-03 Nanostring Technologies, Inc. Methods of treating breast cancer with gemcitabine therapy
CN102719547B (zh) * 2012-07-02 2013-10-09 厦门大学 检测her2基因表达水平的实时荧光定量pcr试剂盒
EP2888391A4 (en) * 2012-08-24 2016-09-14 Univ Utah Res Found COMPOSITIONS AND METHODS RELATING TO BLOOD BIOMARKERS OF BREAST CANCER
WO2014071218A2 (en) * 2012-11-02 2014-05-08 University Of Utah Research Foundation Biomarkers for breast cancer and methods of using same
US20140154681A1 (en) * 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
WO2014118333A1 (en) 2013-02-01 2014-08-07 Sividon Diagnostics Gmbh Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
WO2014186349A1 (en) * 2013-05-13 2014-11-20 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
SG11201601060RA (en) 2013-08-19 2016-03-30 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of tumors
PL2959021T3 (pl) * 2013-08-19 2018-11-30 Biontech Diagnostics Gmbh Sposoby i zestawy do podtypowania molekularnego guzów
EP3036712A4 (en) * 2013-08-20 2017-04-19 The Ohio State Innovation Foundation Methods for predicting prognosis
JP2016537010A (ja) * 2013-09-09 2016-12-01 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット
KR101560880B1 (ko) 2013-10-15 2015-10-19 이화여자대학교 산학협력단 유방암의 예후 판단을 위한 정보를 제공하는 방법
WO2015084968A1 (en) 2013-12-03 2015-06-11 University Of Massachusetts System and methods for predicting probable relationships between items
CA2934626C (en) * 2014-02-18 2023-08-01 Dignity Health Lkb1 related diagnostics and treatments of cancer
EP3146078B1 (en) * 2014-05-17 2019-11-27 The Regents of the University of California Centromere/kinetochore protein genes as markers for cancer diagnosis and prognosis and for treatment selection
CA2968376C (en) 2014-11-21 2020-06-23 Nanostring Technologies, Inc. Enzyme- and amplification-free sequencing
WO2016085841A1 (en) 2014-11-24 2016-06-02 Nanostring Technologies, Inc. Methods and apparatuses for gene purification and imaging
EP3230466A1 (en) * 2014-12-09 2017-10-18 King's College London Breast cancer treatment with taxane therapy
EP3230471B1 (en) 2014-12-12 2019-08-28 Medivation Prostate Therapeutics LLC Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
KR101882755B1 (ko) * 2015-02-27 2018-07-27 연세대학교 산학협력단 유방암의 예후 및 항암화학요법 사용 여부 판단 장치 및 방법
EP3359692A4 (en) * 2015-10-05 2019-05-01 Cedars-Sinai Medical Center METHOD OF CLASSIFYING AND DIAGNOSING CANCER
EP3387168B1 (en) * 2015-12-07 2021-05-12 Ontario Institute for Cancer Research (OICR) Gene signature of residual risk following endocrine treatment in early breast cancer
WO2017189976A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
CN116200462A (zh) 2016-05-16 2023-06-02 纳米线科技公司 用于检测样品中目标核酸的方法
US10934590B2 (en) 2016-05-24 2021-03-02 Wisconsin Alumni Research Foundation Biomarkers for breast cancer and methods of use thereof
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018074865A2 (ko) * 2016-10-21 2018-04-26 서울대학교병원 유방암 예후 예측용 조성물 및 방법
KR102187291B1 (ko) 2016-11-21 2020-12-07 나노스트링 테크놀로지스, 인크. 화학적 조성물 및 이것을 사용하는 방법
ES2674327B2 (es) * 2016-11-28 2018-12-17 Geicam - Grupo Español De Investigacion En Cancer De Mama CES: un índice quimioendocrino basado en PAM50 para el cáncer de mama con receptores hormonales positivos con un riesgo intermedio de recidiva
KR101874716B1 (ko) * 2016-12-14 2018-07-04 연세대학교 산학협력단 유방암 분자아형 분류방법 및 이를 이용한 유방암 분자아형 분류 디바이스
WO2018160925A1 (en) * 2017-03-02 2018-09-07 President And Fellows Of Harvard College Methods and systems for predicting treatment responses in subjects
WO2018165600A1 (en) * 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3066930A1 (en) * 2017-06-16 2018-12-20 Nantomics, Llc Prognostic indicators of poor outcomes in praegnant metastatic breast cancer cohort
WO2019051266A2 (en) 2017-09-08 2019-03-14 Myriad Genetics, Inc. METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES TO PREDICT THE INTEREST OF CHEMOTHERAPY
IT201700109459A1 (it) * 2017-09-29 2019-03-29 Univ Degli Studi Di Perugia Metodo per effettuare prognosi del cancro della mammella, kit ed uso di questi
US20200357484A1 (en) * 2017-11-08 2020-11-12 Koninklijke Philips N.V. Method for simultaneous multivariate feature selection, feature generation, and sample clustering
WO2019165366A1 (en) * 2018-02-23 2019-08-29 Beth Israel Deaconess Medical Center Drug efficacy evaluations
KR20210061962A (ko) 2018-05-14 2021-05-28 나노스트링 테크놀로지스, 인크. 화학 조성물 및 이의 사용 방법
KR101966589B1 (ko) * 2018-06-20 2019-04-05 연세대학교 산학협력단 유방암 분자아형 분류방법 및 이를 이용한 유방암 분자아형 분류 디바이스
SG11202106398WA (en) * 2018-11-04 2021-07-29 Pfs Genomics Inc Methods and genomic classifiers for prognosis of breast cancer and predicting benefit from adjuvant radiotherapy
CN109801680B (zh) * 2018-12-03 2023-02-28 广州中医药大学(广州中医药研究院) 基于tcga数据库的肿瘤转移复发预测方法及系统
WO2020178399A1 (en) 2019-03-05 2020-09-10 Norwegian University Of Science And Technology (Ntnu) Breast cancer signature genes
CN109913551A (zh) * 2019-03-26 2019-06-21 深圳大学 乳腺癌分型的核酸组合物、乳腺癌分型试剂盒及其使用方法
CN111508555A (zh) * 2020-04-15 2020-08-07 淮南师范学院 一组用于度量生物分子集的网络拓扑学特性的方法
CN112626218A (zh) * 2021-01-07 2021-04-09 浙江科技学院 一种用于预测胰腺癌转移风险的基因表达分类器、体外诊断试剂盒
CN112735529A (zh) * 2021-01-18 2021-04-30 中国医学科学院肿瘤医院 乳腺癌预后模型的构建方法及应用方法、电子设备
RU2762317C1 (ru) * 2021-02-24 2021-12-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в основном опухолевом узле у больных раком молочной железы
IL306090A (en) * 2021-03-25 2023-11-01 Oncxerna Therapeutics Inc Targeted cancer treatments
WO2023250397A1 (en) * 2022-06-21 2023-12-28 Bioventures, Llc Methods for the molecular subtyping of tumors from archival tissue
CN115144599B (zh) * 2022-09-05 2023-01-06 西湖大学 蛋白组合在制备对儿童甲状腺癌进行预后分层的试剂盒中的用途及其试剂盒、系统

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US20040235039A1 (en) 1990-03-20 2004-11-25 Regents Of The University Of California Chromosome-specific staining to detect genetic rearrangements
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US6025126A (en) 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix Inc N D Ges D Staat Verfahren zur Herstellung von Polymerarrays
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6033860A (en) 1997-10-31 2000-03-07 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU2004248120B2 (en) 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2574447A1 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
JP2006141210A (ja) 2004-11-16 2006-06-08 Hitachi Ltd キメラ遺伝子の検出方法
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
US8986926B2 (en) 2005-12-23 2015-03-24 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
EP1963531B1 (en) 2005-12-23 2011-09-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
WO2007084992A2 (en) 2006-01-19 2007-07-26 The University Of Chicago Prognosis and therapy predictive markers and methods of use
WO2008006517A2 (en) 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
AU2008237018B2 (en) 2007-04-10 2014-04-03 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
JP5740302B2 (ja) * 2008-05-30 2015-06-24 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル 乳癌の予後を予測するための遺伝子発現プロフィール
CA2733609C (en) 2008-08-14 2018-03-06 Nanostring Technologies, Inc. Stable nanoreporters
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
WO2010039275A1 (en) 2008-10-03 2010-04-08 Oligonix, Inc. Method, array and system for detecting intergenic fusions
EP2358199A2 (en) 2008-11-02 2011-08-24 Optimata Ltd. Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf)
CA2807557C (en) 2009-08-06 2019-09-17 Partha S. Ray Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
US20110129822A1 (en) 2009-12-01 2011-06-02 Precision Therapeutics, Inc. Multi drug response markers for breast cancer cells
EP2558599A4 (en) 2010-04-14 2013-11-13 Nuvera Biosciences Inc METHODS OF ASSESSING ANTICANCER THERAPY RESPONSE
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
WO2012135340A2 (en) 2011-03-28 2012-10-04 Nanostring Technologies, Inc. Compositions and methods for diagnosing cancer
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
AU2013266419B2 (en) 2012-05-22 2018-09-27 British Columbia Cancer Agency Branch NANO46 genes and methods to predict breast cancer outcome
WO2014005010A2 (en) 2012-06-29 2014-01-03 Nanostring Technologies, Inc. Methods of treating breast cancer with gemcitabine therapy
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
JP2016537010A (ja) 2013-09-09 2016-12-01 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット

Also Published As

Publication number Publication date
US20220213563A1 (en) 2022-07-07
AU2009262894A1 (en) 2009-12-30
AU2009262894B2 (en) 2014-01-30
US20230250484A1 (en) 2023-08-10
JP6140202B2 (ja) 2017-05-31
US20110145176A1 (en) 2011-06-16
US20190264290A1 (en) 2019-08-29
JP2011524162A (ja) 2011-09-01
PL2297359T4 (pl) 2014-07-31
HRP20140140T1 (en) 2014-05-23
EP2664679B1 (en) 2017-11-08
DK2297359T3 (en) 2014-02-24
EP2297359A1 (en) 2011-03-23
US20160168645A1 (en) 2016-06-16
US9631239B2 (en) 2017-04-25
SI2297359T1 (sl) 2014-05-30
CA2725760C (en) 2019-07-02
EP2664679A1 (en) 2013-11-20
ES2650610T3 (es) 2018-01-19
JP2017127330A (ja) 2017-07-27
JP5740302B2 (ja) 2015-06-24
PT2297359E (pt) 2014-03-19
PL2297359T3 (pl) 2014-07-31
EP2297359B1 (en) 2013-11-13
JP2015119716A (ja) 2015-07-02
US20200040407A1 (en) 2020-02-06
CA2725760A1 (en) 2009-12-30
ES2457534T3 (es) 2014-04-28
WO2009158143A1 (en) 2009-12-30
US20160153051A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
CY1114993T1 (el) Προφιλ εκφρασης γονιδιου για να προβλεπονται εκβασεις καρκινου μαστου
MX369628B (es) Genes nano46 y metodos para predecir el resultado del cancer de mama.
Peneder et al. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
ES2700617T3 (es) Evaluación de la actividad de la ruta de señalización celular utilizando un modelo probabilístico de la expresión del gen objetivo
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
Gage et al. A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay
JP2017503527A5 (el)
MX2011011571A (es) Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
CY1117525T1 (el) Διαγνωση εμβρυϊκης χρωμοσωμικης ανευπλοειδιας χρησιμοποιωντας γονιδιωματικη αλληλουχιση
Zhao et al. Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
MX338883B (es) Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
WO2015087088A3 (en) Prostate cancer classification
JP2019537108A5 (el)
AR085818A1 (es) Hipometilacion de line-1 como biomarcador del comienzo temprano de cancer colorrectal
Pasquali et al. Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy for cutaneous melanoma
Chiam et al. Identification of microRNA biomarkers of response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing
Montserrat et al. Present and future of personalized medicine in CLL
Umamaheswari et al. Enhanced firefly algorithm (EFA) based gene selection and adaptive neuro neutrosophic inference system (ANNIS) prediction model for detection of circulating tumor cells (CTCs) in breast cancer analysis
US20180371553A1 (en) Methods and compositions for the analysis of cancer biomarkers
ES2662571T3 (es) Métodos de evaluación de la receptividad endometrial de una paciente tras una hiperestimulación ovárica controlada
WO2009054474A1 (ja) アレル判定装置及び方法、ならびに、コンピュータプログラム
CY1123191T1 (el) Δοκιμασιες υποδοχεων στεροειδων για ανιχνευση κυτταρων ογκου
WO2020123880A3 (en) Genomic rearrangements associated with prostate cancer and methods of using the same
BRPI0507392A (pt) método e kit para determinar a possibilidade de metástase de cáncer em um indivìduo